Upgrade to SI Premium - Free Trial

Marker Therapeutics (MRKR) Misses Q3 EPS by 26c

November 14, 2024 9:30 PM

Marker Therapeutics (NASDAQ: MRKR) reported Q3 EPS of ($0.26). Revenue for the quarter came in at $1.93 million.

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

Categories

Earnings